Epstein Barr virus nRNA

Drug Profile

Epstein Barr virus nRNA

Alternative Names: EBV nanoRNA; EBV nRNA; EBV-nRNA - Lakewood-Amedex

Latest Information Update: 31 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lakewood Amedex
  • Class Antisense RNA
  • Mechanism of Action Epstein Barr virus replication inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Nasopharyngeal cancer

Most Recent Events

  • 31 May 2013 EBV nRNA is still in phase I development for Nasopharyngeal cancer
  • 28 Aug 2009 Phase-I trials in Nasopharyngeal cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top